Silence Therapeutics PLC(SLN) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Company further extends cash guidance into 2028 8 May 2025 LONDON, Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. "Silence delivered another strong quarter focused on cl ...